Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
TERMINATED
NCT04254549
PHASE2
Rifaximin in Patients With Diabetic Gastroparesis
Sponsor: Mayo Clinic
View on ClinicalTrials.gov
Summary
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Official title: Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2019-06-14
Completion Date
2025-04-11
Last Updated
2026-06-22
Healthy Volunteers
No
Conditions
Interventions
DRUG
Rifaximin
550 mg by mouth three times daily for 14 days
DRUG
Placebo
By mouth three times daily for 14 days
Locations (1)
Mayo Clinic in Florida
Jacksonville, Florida, United States